Fidelity Investments
CYCN icon

Fidelity Investments’s Cyclerion Therapeutics CYCN Stock Holding History

Fidelity Investments’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.28K Hold
4,740
– – ﹤0.01% 4844
2025
Q4 		$6.02K Sell
4,740
-6
-0.1% -$11 ﹤0.01% 4854
2025
Q3 		$10.9K Buy
4,746
+6
+0.1% +$16 ﹤0.01% 4582
2025
Q2 		$13.8K Sell
4,740
-200
-4% -$597 ﹤0.01% 4425
2025
Q1 		$12.2K Buy
4,940
+200
+4% +$595 ﹤0.01% 4434
2024
Q4 		$15.3K Sell
4,740
-152,896
-97% -$426K ﹤0.01% 4295
2024
Q3 		$407K Sell
157,636
-3,783
-2% -$11.1K ﹤0.01% 2937
2024
Q2 		$368K Sell
161,419
-908
-0.6% -$2.58K ﹤0.01% 2837
2024
Q1 		$519K Sell
162,327
-522
-0.3% -$1.67K ﹤0.01% 2706
2023
Q4 		$546K Sell
162,849
-1,700
-1% -$4.91K ﹤0.01% 2661
2023
Q3 		$559K Sell
164,549
-400
-0.2% -$1.44K ﹤0.01% 2601
2023
Q2 		$678K Sell
164,949
-4,569
-3% -$23.7K ﹤0.01% 2569
2023
Q1 		$1.47M Sell
169,518
-1,530
-0.9% -$19.3K ﹤0.01% 2441
2022
Q4 		$2.24M Buy
171,048
+355
+0.2% +$4.2K ﹤0.01% 2345
2022
Q3 		$2.94M Buy
170,693
+43,807
+35% +$753K ﹤0.01% 2321
2022
Q2 		$1.39M Sell
126,886
-3,865
-3% -$55.4K ﹤0.01% 2594
2022
Q1 		$2.9M Sell
130,751
-120
-0.1% -$2.89K ﹤0.01% 2503
2021
Q4 		$4.5M Sell
130,871
-1,560
-1% -$73.7K ﹤0.01% 2395
2021
Q3 		$8.13M Sell
132,431
-1,310
-1% -$85.7K ﹤0.01% 2196
2021
Q2 		$10.4M Sell
133,741
-2,575
-2% -$161K ﹤0.01% 2089
2021
Q1 		$7.61M Buy
136,316
+330
+0.2% +$24.8K ﹤0.01% 2139
2020
Q4 		$8.32M Sell
135,986
-850
-0.6% -$57.9K ﹤0.01% 2027
2020
Q3 		$16.6M Sell
136,836
-370
-0.3% -$42.3K ﹤0.01% 1638
2020
Q2 		$16.2M Sell
137,206
-1
-0% -$84 ﹤0.01% 1632
2020
Q1 		$7.27M Buy
137,207
+10,633
+8% +$759K ﹤0.01% 1801
2019
Q4 		$6.88M Sell
126,574
-10,265
-8% -$959K ﹤0.01% 1971
2019
Q3 		$33.2M Sell
136,839
-23
-0% -$4.97K ﹤0.01% 1363
2019
Q2 		$31.3M Buy
+136,862
New +$38.7M ﹤0.01% 1428

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Fidelity Investments's CYCN Position: Q1 2026 in Review

Fidelity Investments held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 4,740 shares worth $7.28K. The position accounts for ﹤0.01% of the portfolio, ranked #4844.

Fidelity Investments first reported a position in CYCN in Q2 2019 and has held it in 28 quarters since. The position peaked at $33.2M in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Fidelity Investments held 4,740 shares of Cyclerion Therapeutics worth $7.28K as of Q1 2026.
  • Fidelity Investments left its Cyclerion Therapeutics share count unchanged in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4844 holding.
  • Fidelity Investments first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Fidelity Investments's Cyclerion Therapeutics position peaked at $33.2M in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.